Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2024 01:30 ET | Source: Custom Market Insights

[Latest] Global Serological Testing Market Size/Share Worth USD 8,100 Million by 2033 at a 6.70% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Serological Testing Market Size, Trends and Insights By Technology (ELISA, NAT,...
September 20, 2024 05:03 ET | Source: inbiome

Inbiome, developing a new PCR technology capable of simultaneous identification of hundreds of bacterial pathogens in a single test, welcomes Professor Dr. Carl Wittwer to its Advisory Board

Amsterdam, The Netherlands, September 20, 2024. Inbiome, a pioneer in advanced molecular diagnostics, today announced the appointment of Professor Dr. Carl Wittwer (picture), a global authority in PCR...
June 03, 2024 08:14 ET | Source: AUROBAC THERAPEUTICS

AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim

AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
February 20, 2024 04:00 ET | Source: AKAMPION

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
December 04, 2023 04:00 ET | Source: AKAMPION

EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001

Presentation at the World Vaccine Congress West Coast2023EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodiesNovel...
October 05, 2023 09:00 ET | Source: Exbaq LLC

Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections

Vaccine Stimulates the Body’s Macrophages, Engulfing and Killing Gram Positive/Negative Bacteria, and FungiVaccine provides protection against infections within 24hours and protection lasts for up to...
August 10, 2023 16:15 ET | Source: OpGen, Inc.

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
August 03, 2023 07:30 ET | Source: OpGen, Inc.

OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
May 08, 2023 07:30 ET | Source: OpGen, Inc.

OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time

ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
April 05, 2023 07:30 ET | Source: OpGen, Inc.

OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND

Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen,...

Next Page keyboard_arrow_right